139 related articles for article (PubMed ID: 18005268)
21. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
Grimaud E; Soubigou L; Couillaud S; Coipeau P; Moreau A; Passuti N; Gouin F; Redini F; Heymann D
Am J Pathol; 2003 Nov; 163(5):2021-31. PubMed ID: 14578201
[TBL] [Abstract][Full Text] [Related]
22. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
Giuliani N; Colla S; Rizzoli V
Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of bone destruction in multiple myeloma.
Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
[TBL] [Abstract][Full Text] [Related]
24. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
Bolzoni M; Storti P; Bonomini S; Todoerti K; Guasco D; Toscani D; Agnelli L; Neri A; Rizzoli V; Giuliani N
Exp Hematol; 2013 Apr; 41(4):387-97.e1. PubMed ID: 23178378
[TBL] [Abstract][Full Text] [Related]
25. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
26. TRAIL produced from multiple myeloma cells is associated with osteolytic markers.
Kawano Y; Ueno S; Abe M; Kikukawa Y; Yuki H; Iyama K; Okuno Y; Mitsuya H; Hata H
Oncol Rep; 2012 Jan; 27(1):39-44. PubMed ID: 21993926
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
[TBL] [Abstract][Full Text] [Related]
28. DKK1 in multiple myeloma.
Lu CM
N Engl J Med; 2004 Apr; 350(14):1464-6; author reply 1464-6. PubMed ID: 15074001
[No Abstract] [Full Text] [Related]
29. Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention.
Zhou F; Meng S; Song H; Claret FX
Blood Rev; 2013 Nov; 27(6):261-7. PubMed ID: 24054128
[TBL] [Abstract][Full Text] [Related]
30. [Bone disease in multiple myeloma and its mechanism].
Abe M
Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
[TBL] [Abstract][Full Text] [Related]
31. Identification of new targets for therapy of osteolytic bone disease in multiple myeloma.
Hjertner Ø; Standal T; Børset M; Sundan A; Waage A
Curr Drug Targets; 2005 Sep; 6(6):701-11. PubMed ID: 16178802
[TBL] [Abstract][Full Text] [Related]
32. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
Wittrant Y; Théoleyre S; Chipoy C; Padrines M; Blanchard F; Heymann D; Rédini F
Biochim Biophys Acta; 2004 Sep; 1704(2):49-57. PubMed ID: 15363860
[TBL] [Abstract][Full Text] [Related]
33. DKK1 in multiple myeloma.
Hofbauer LC; Neubauer A; Schoppet M
N Engl J Med; 2004 Apr; 350(14):1464-6; author reply 1464-6. PubMed ID: 15074002
[No Abstract] [Full Text] [Related]
34. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma.
Roux S; Meignin V; Quillard J; Meduri G; Guiochon-Mantel A; Fermand JP; Milgrom E; Mariette X
Br J Haematol; 2002 Apr; 117(1):86-92. PubMed ID: 11918537
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.
Fowler JA; Mundy GR; Lwin ST; Edwards CM
Cancer Res; 2012 May; 72(9):2183-9. PubMed ID: 22374979
[TBL] [Abstract][Full Text] [Related]
36. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
37. [Bone marrow plasma concentrations of Dickkopf1 in patients with multiple myeloma].
Dun XY; Jiang H; Hou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 38(5):453-8. PubMed ID: 19830856
[TBL] [Abstract][Full Text] [Related]
38. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
Terpos E; Politou M; Viniou N; Rahemtulla A
Leuk Lymphoma; 2005 Dec; 46(12):1699-707. PubMed ID: 16263571
[TBL] [Abstract][Full Text] [Related]
39. Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.
Palma BD; Guasco D; Pedrazzoni M; Bolzoni M; Accardi F; Costa F; Sammarelli G; Craviotto L; De Filippo M; Ruffini L; Omedè P; Ria R; Aversa F; Giuliani N
Leukemia; 2016 Feb; 30(2):409-16. PubMed ID: 26419509
[TBL] [Abstract][Full Text] [Related]
40. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa S; Kitazawa R
J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]